Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PRS38 Cost-Effectiveness of Once-Daily Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma

Autor: H. Kaur, I. Hasani, R. Olivenstein, M. Mtibaa, R. Ishikawa, J. Marvel, M. Muthukumar, Saransh Gupta

Publikováno v: Value in Health. 23:S723-S724

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e8ebc05743432700a06aaec2ae303c8
https://doi.org/10.1016/j.jval.2020.08.1918

Zobrazit plný text záznamu

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

Autor: Chad Patel, Silvia Jimenez Merino, M Mtibaa, Carmela Nappi, Francesco Saverio Mennini, Giulia Attinà, Jason Foo, Kirsten H Herrmann, Martin J. Bergman, Christoph Baerwald, Denis Choquette, José Manuel Rodriguez-Heredia, Laure Weijers

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Rheumatology International

Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden. The Abatacept versus Adalimumab Comparison in Biologic-Naïv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee57b8607012b589d7180bc0b480d00
https://doi.org/10.1007/s00296-017-3739-9

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

220 Cost per response for abatacept versus adalimumab in patients with seropositive erosive, early rheumatoid arthritis in the United States, Germany, Spain and Canada

Autor: M Mtibaa, Evo Alemao, Carlos Polanco Sanchez, José Manuel Rodriguez-Heredia, Roelien Postema, Christoph Baerwald, Jason Foo, Kirsten H Herrmann

Publikováno v: Rheumatology. 57

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68122f82e59c50effed3ff9a2b76b66c
https://doi.org/10.1093/rheumatology/key075.444

Zobrazit plný text záznamu

PCN278 REAL WORLD TREATMENT PATTERNS FOR FIRST LINE (1L) RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PATIENTS

Autor: C. Polanco, A. Bailey, M. Contente, J. Hall, M. Mtibaa, Prianka Singh, P. Di Rienzo, H. Bailey

Publikováno v: Value in Health. 22:S108-S109

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14546fee22471c676b670c0ecc25fee6
https://doi.org/10.1016/j.jval.2019.04.397

Zobrazit plný text záznamu

AB0397 Abatacept shows better sustainability than tnf inhibitors when used following initial biologic dmard failure in the treatment of rheumatoid arthritis: 8 years of real-world observations from the rhumadata® clinical database and registry

Autor: J.-P. Raynauld, Roelien Postema, D. Sauvageau, M Mtibaa, Frédéric Massicotte, J.-P. Pelletier, M-A Rémillard, E Muratti, Evo Alemao, Boulos Haraoui, Louis Bessette, L. Coupal, Έ. Villeneuve, A Turcotte, Denis Choquette

Publikováno v: Abstracts Accepted for Publication.

Background In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of an alternative agent. Traditionally, a second anti-TNF was the preferred option, but recent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c19b7f8a057dab3945167227e4eb72b
https://doi.org/10.1136/annrheumdis-2017-eular.2379

Zobrazit plný text záznamu

FRI0230 Retention rates of tnf inhibitors and abatacept used as a first biologic dmard in the treatment of rheumatoid arthritis: 8 years of experience from the rhumadata® registry

Autor: M Mtibaa, E Muratti, J.-P. Pelletier, Frédéric Massicotte, J.-P. Raynauld, Roelien Postema, Boulos Haraoui, M-A Rémillard, Evo Alemao, L. Coupal, Louis Bessette, Έ. Villeneuve, D. Sauvageau, A Turcotte, Denis Choquette

Publikováno v: Poster Presentations.

Background Sustainability of treatment is important to consider when selecting a therapy for chronic conditions such as RA. Sustainability is a useful clinical marker for both long-term efficacy and safety. A recently published randomized controlled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::daeed4a31ad2ab389bacb20acc08a961
https://doi.org/10.1136/annrheumdis-2017-eular.2326

Zobrazit plný text záznamu

Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada

Autor: Peter Quon, M Mtibaa, Andriy Moshyk, Hoa H. Le, Vincent Raymond

Publikováno v: Journal of medical economics. 19(6)

Background and objective Venous thromboembolism (VTE) is associated with long-term clinical and economic burden. Clinical guidelines generally recommend at least 3 months of anticoagulation, but, in clinical practice, concerns over bleeding risk ofte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253dddfc8e0571f16cbc419c4cedfdcd
https://pubmed.ncbi.nlm.nih.gov/26761644

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání